Most head and neck cancers are derived from the mucosal epithelium in the oral cavity,
pharynx and larynx and are known collectively as head and neck squamous cell carcinoma …

Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. While this approach …

PURPOSE To provide evidence-based recommendations for practicing physicians and
other healthcare providers on the management of salivary gland malignancy. METHODS …

In the setting of conventional radiation therapy, even when combined with immunotherapy,
head and neck cancer often recurs locally and regionally. Elective nodal irradiation (ENI) is …

Abstract Background and purpose The Meta-Analysis of Chemotherapy in squamous cell
Head and Neck Cancer (MACH-NC) demonstrated that concomitant chemotherapy (CT) …

PURPOSE The regimens approved for the treatment of advanced head and neck squamous
cell carcinoma are accessible to only 1%-3% of patients in low-and middle-income countries …

Five-year survival for human papilloma virus-unrelated head and neck squamous cell
carcinomas remain below 50%. We assessed the safety of administering combination …

Immunotherapy has changed the treatment landscape of Head and Neck cancer (HNC).
Different immune checkpoint inhibitors targeting PD-1/PD-L1 axis have been approved for …

Simple Summary Even with recent advances, there are urgent needs for novel therapies to
improve overall survival and decrease toxicities in the management of head and neck …

Background Colorectal cancer (CRC), the 3rd most universal cancer globally, accounts for
approximately 10% of newly diagnosed cancer incidences each year. Identifying biomarkers …